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Short Communication
Effective prevention of the nephrotoxicity of
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2-mercaptoethane-sulfonate (MESNA) in rats
S.R. Kempf, S. Ivankovic, M. Wiessler & D. Schmahl
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The nephrotoxic activity of cis-diammine-dichloro-
platinum (CDDP), an important cytostatic agent in
modern cancer chemotherapy, has most commonly
limited the effective use of this drug (Rozencweig et
al., 1977; Gonzalez-Vitale et al., 1977; Campbell et
al., 1983; Offerman et al., 1984). As in man, typical
pathological changes in the kidneys after CDDP
application can also be found in laboratory animals
(Kociba & Sleight, 1971; Choie et al., 1981;
Goldstein & Gilbert, 1983). These renal lesions are
dose and time dependant, and mainly localized in
the outer stripe of the medulla. By pretreatment
hydration with 0.9% NaCl and forced diuresis
particularly, the toxic activity of CDDP on the
kidneys of human patients can be partially reduced,
but not completely inhibited (Hayes et al., 1977;
Ostrow et al., 1981; Ozols et al., 1984).
Sodium 2-mercaptoethane-sulfonate (INN:
MESNA; Uromitexan' (Asta-Werke AG, FRG,
and Boehringer Ingelheim Hospital Division, UK
and Eire) is an almost non-toxic thio compound. It
is already used in patients who receive oxaza-
phosphorine cytostatics, such as cyclophosphamide
and ifosfamide, to protect the efferent urinary tract,
especially the bladder, against the toxic metabolites
of these chemotherapeutic agents (Scheef et al.,
1979; Brock, 1980). Until now, protection against
the nephrotoxicity of CDDP through MESNA has
not been established.
CDDP, being a heavy-metal complex, might
easily be chelated by sulfhydryl containing com-
pounds, eg by the highly reactive thio-compound
MESNA. The only known metabolite of MESNA
is MESNA disulfide, which is not capable of
reaction (Brock et al., 1982). After oral adminis-
tration of MESNA, this inactive metabolite occurs
almost solely in the blood. So it could be antici-
pated that intravascular DIMESNA would not
react with CDDP or with intravenously
administered antiemetics, which are absolutely
necessary in humans, because of the emetic effects
of cis-platin. After i.v. administration of MESNA,
the disulfide is also formed spontaneously by auto-
oxidation and found predominantly in the blood
stream (Brock et al., 1982). It is eliminated through
the kidneys by glomerular filtration, and, to a great
extent, reduced to MESNA during excretion. In the
tubular lumen MESNA would then be available for
reactions, eg with CDDP, which mainly damages
the renal tubules.
In our investigations we managed to completely
prevent renal damage in BD IX rats after a single
dose of 3mg CDDPkg-t body weight i.p. (half
of LD50 in this strain) by additional per os
administration of MESNA. This protection showed
a clearly recognizable dose/effect relationship,
indicating that low doses of MESNA had only
partially protective effects on the kidneys of rats.
The histological findings in the kidneys of the 45
animals, listed in Table I (9 animals in each group)
were divided into 4 classes, according to the extent
of the pathological changes:
(i) Severe renal changes: showing tubular necrosis,
flattened tubular epithelium, massive dilation of
tubular lumina (also confluating cysts), which
contain necrotic epithelial cells. Also nuclear
hyperchromasia and oedematous interstitium with
focal lymphocytic infiltrations.
(ii) Intermediate renal changes: with focal
necrosis and flattening of tubular epithelium;
moderate dilatation of tubular lumina, without
confluating cysts; no nuclear atypias. The
interstitium is mildly oedematous and shows focal
lymphocytic infiltrations.
(iii) Minimal renal changes: The tubules are
relatively normal, there is, perhaps some slightly
flattened tubular epithelium, but no tubular dilata-
tion and no nuclear atypias. Slightly oedematous
interstitium with mild focal lymphocytic
infiltrations.
(iv) No changes: normal histological findings in
the kidneys.
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Table I Histopathological changes in the kidneys of rats after a single dose ofCDDP.
CDDP IJx3mgkg 1i.p.:
Doses (kg ) +H20 +MESNA +MESNA +MESNA +MESNA
Day 1-4 12mId-1 150mgd-1 300mgd-1 600mgd-1 1200mgd-
Day 5-12: 4mld-1 50mgd-1 100mgd- 200mgd-1 400mgd-
Animal
no. Scale ofrenal changes
I +++ (+) + + 0
2 + ++ 0 (+) 0
3 ++ + ++ (+) 0
4 ++ + ++ + 0
5 ++ ++ (+) 0 0
6 ++ ++ + + 0
7 + (+) (+) 0 0
8 ++ + (+) + 0
9 ++ ++ ++ (+) 0
aPlatinex®; + +severe renal change; +intermediate changes; (+)minimal renal changes;
0 no changes (normal kidney).
It was possible to completely protect the kidneys of
rats from CDDP-induced damage with sufficient
doses of MESNA. (Table I)
In addition, two groups of animals, which
received 3 times weekly I mg CDDPkg 1 i.p. for 3
weeks, were compared with one another: Maximally
tolerated pretreatment hydration with 0.9% NaCl
was given to the animals of group 1, while the
animals of group 2 received MESNA, dissolved in
an equal quantity of water. Animals were killed 12
days after the last application of CDDP. Histo-
logical examination of the kidneys of all animals
showed severe and intermediate renal changes in
87% of the aniamsl of group 1 and only in 11% of
the animals of group 2.
Minimal or no changes were found for 13% in
group 1 (no animal without renal changes) and in
89% of the animals of group 2 (70% of which had
no renal lesions at all).
In view of the pharmacokinetics of both sub-
stances (MESNA and CDDP), MESNA was given
orally in these experiments, 400mgkg- body
weight, 2h before each CDDP application, and
then every 4h 200mgkg-1 p.o. (4 times daily) up
to the 4th day after the last CDDP administration.
As a follow-up treatment it was found necessary to
maintain protection of the kidneys for an additional
12 days by a single daily dose of 400mg
MESNAkg 1 body weight p.o.
To prove that MESNA does not alter the
antitumour efficacy of CDDP, we used the SC
tumour model 2S 241/38, adenocarcinoma of the
stomach. This tumour had been induced by N-
Methyl-N'-nitro-N-nitroso-guanidine (MNNG) in
our laboratory and has now been transplanted s.c.
to the 35th passage in BD IX rats. In previous
experiments, CDDP proved to be effective against
this adenocarcinoma. In 40 BD IX rats this tumour
was treated with 3 x 1 mg CDDPkg-1 week -1 for 3
weeks. Twenty animals received additional oral
MESNA according to our schedule (see above), the
other 20 animals received pretreatment hydration
with a balanced electrolyte solution (2ml 100g-
p.o. immediately before each CDDP adminis-
tration). There was no difference in tumour
inhibition between the two groups.
To support these findings, we are testing CDDP
and additional nephroprotection by MESNA on
leukaemia L1210, which is well known for its
sensitivity to CDDP treatment (Rosenberg et al.,
1969). These data will be reported subsequently.
We thank the Bristol Laboratories for the supply of
Platinexg.
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